IDH1突变AML:除前述治疗方案,可以选择艾伏尼布(500 mg,第1~28天)联合阿扎胞苷(75 mg·m−2·d−1,7 d),每28 d 1个周期(证据等级1a)或艾伏尼布单药治疗[41](证据等级2b)。. This evidence concerns the gene IDH1 and acute myeloid leukemia.